Celltrion
South Korea's leading biosimilar manufacturer challenging global pharma giants
Company Overview
Celltrion is South Korea's largest biopharmaceutical company and a global pioneer in biosimilar development. The company developed the world's first antibody biosimilar (Remsima/Inflectra) and has built a portfolio of biosimilars for autoimmune diseases, oncology, and ophthalmology. Celltrion's vertically integrated model — from development through manufacturing to direct commercialization — has disrupted the traditional pharmaceutical value chain.
Why This Company Matters
Celltrion has proven that Asian companies can compete with global pharma giants in complex biologic drug development, opening new markets for affordable biologics.
Key Focus Areas
Peer Companies
Signal Timeline
0 totalNo signals tracked yet for this company.
Signals will appear here as official announcements are indexed.
We are actively monitoring this company's official channels. Signals will appear as they are discovered.
Get notified when new signals are published for this company.